Cipla API facility in Bengaluru gets EIR from USFDA

Cipla had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.

NEW DELHI: Cipla Ltd on Sunday announced the closure of inspection by the US health regulator at the company's API manufacturing facility in Bengaluru.

"Following the inspection by the United States Food and Drug Administration (USFDA) at Company's API manufacturing facility in Virgonagar, Bengaluru, from July 15- 19, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the company said in a filing to the BSE.

Read Also: Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

The company had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.

Read Also: Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat a diabetic foot ulcer